FDA approved Foundayo (orforglipron) on April 1, 2026 for weight reduction and maintenance in adults with obesity or overweight with at least one comorbidity, per the agency's 2026 novel drug approvals list — the first widely expected oral GLP-1 for chronic weight management, and the one designed to be manufactured at tablet scale rather than in injectable pens.
This article publishes information, not medical advice. Weight-management medications require screening for contraindications, a titration plan, and monitoring; decide with a clinician who can see your full medication list.
Why does an oral GLP-1 change the market?
Injectable GLP-1 agonists such as semaglutide and tirzepatide transformed obesity treatment but face two constraints: injection logistics and, more consequentially, manufacturing capacity for the specialized injector pens. Orforglipron is a small molecule taken as a daily tablet, which means it can be produced on standard pharmaceutical lines — the reason analysts expected it to expand supply and, eventually, lower the price floor for the category.
Related stories: FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL · FDA Approved Veppanu for the Mutation That Ends Hormone Therapy's Run.
What do the numbers look like?
Orforglipron's phase 3 program reported mean weight loss in the range of high-teens percentages of body weight at the highest dose — below the strongest injectable results, which approach 20 percent and beyond, but comfortably above older oral options. Like all GLP-1 agents, it carries gastrointestinal side effects during titration, and the trials reinforce a fact this publication keeps repeating: discontinuation drives weight regain, so the drug works while it is taken.
Will insurance cover it?
Coverage, not efficacy, will decide most people's access. Employer plans have been retreating from GLP-1 coverage because of cost, and even with a pill, list prices in this category start high. Check whether your plan's 2026 formulary lists Foundayo, whether it sits on a specialty tier with prior authorization, and whether a documented comorbidity — sleep apnea, hypertension, type 2 diabetes — changes your coverage argument.
What to watch next
Watch the label's language on cardiovascular outcomes, the category's key open question, and Medicare Part D coverage decisions, since a 2022 law bars Part D from covering drugs for weight loss alone unless another indication applies. A diabetes or cardiovascular indication for orforglipron would redraw that line — and it is the most consequential follow-up filing to track this year.
For more context, read FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL.
For more context, read utebzi fda approval.
For more context, read orzeyful fda approval.